YKL-40-A Protein in the Field of Translational Medicine: A Role As a Biomarker in Cancer Patients?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 28

PMID 24281168

Citations 31

Authors

Nicolai A Schultz

Julia S Johansen

Affiliations

Soon will be listed here.

Abstract

YKL-40 is a 40 kDa glycoprotein produced by cancer cells, inflammatory cells and stem cells. It probably has a role in cell proliferation and differentiation, inflammation, protection against apoptosis, stimulation of angiogenesis, and regulation of extracellular tissue remodelling. Plasma levels of YKL-40 are often elevated in patients with localized or advanced cancer compared to age-matched healthy subjects. Several studies have demonstrated that high plasma YKL-40 is an independent prognostic biomarker of short survival in patients with different types of cancer. However, there is not yet sufficient data to support determination of plasma YKL-40 outside research projects as a biomarker for screening of gastrointestinal cancer and determination of treatment response and poor prognosis before or during treatment and follow-up. Plasma YKL-40 is also elevated in patients with other diseases than cancer, e.g., severe infections, cardiovascular disease, diabetes, chronic obstructive lung disease, asthma, liver fibrosis and rheumatoid arthritis. Co-morbidity should therefore always be considered in patients with cancer, since other sources than cancer cells can increase plasma YKL-40 levels. Future focused translational research projects combining basic and clinical research are needed in a joint effort to answer questions of the complex function and regulation of YKL-40 and the question if plasma YKL-40 is a clinical useful biomarker in patients with cancer.

Citing Articles

YKL-40 inhibits melanoma progression and metastasis by inducing immune cell infiltration in a mouse model.

Zhang H, Zhao X, Shi M, Han Y, Lu K, Wang H Sci Rep. 2025; 15(1):7426.

PMID: 40033096 PMC: 11876687. DOI: 10.1038/s41598-025-92522-7.

Heparin-binding of the human chitinase-like protein YKL-40 is allosterically modified by chitin oligosaccharides.

Magnusdottir U, Thormodsson F, Kjalarsdottir L, Filippusson H, Gislason J, Oskarsson K Biochem Biophys Rep. 2025; 41():101908.

PMID: 39811191 PMC: 11732221. DOI: 10.1016/j.bbrep.2024.101908.

CHI3L1 in Multiple Sclerosis-From Bench to Clinic.

Jatczak-Pawlik I, Jurewicz A, Domowicz M, Ewiak-Paszynska A, Stasiolek M Cells. 2025; 13(24.

PMID: 39768177 PMC: 11674340. DOI: 10.3390/cells13242086.

Prognostic and predictive role of YKL-40 in anal squamous cell carcinoma: a serological and tissue-based analysis in a multicentric cohort.

Gambella A, Senetta R, Falco E, Ricci A, Mangherini L, Tampieri C Front Med (Lausanne). 2024; 11:1372195.

PMID: 39045410 PMC: 11263350. DOI: 10.3389/fmed.2024.1372195.

Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.

Kazakova M, Ivanova T, Dikov D, Molander D, Simitchiev K, Sbirkov Y Heliyon. 2024; 10(5):e27570.

PMID: 38495157 PMC: 10940939. DOI: 10.1016/j.heliyon.2024.e27570.

References

Johansen J, Krabbe K, Moller K, Pedersen B . Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol. 2005; 140(2):343-8. PMC: 1809363. DOI: 10.1111/j.1365-2249.2005.02763.x. View

Harvey S, Whaley J, Eberhardt K . The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol. 2000; 29(6):391-3. DOI: 10.1080/030097400447606. View

Johansen J, Hoyer P, Larsen L, Price P, Mollgard K . YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem. 2007; 55(12):1213-28. DOI: 10.1369/jhc.7A7245.2007. View

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

Johansen J, Milman N, Hansen M, Garbarsch C, Price P, Graudal N . Increased serum YKL-40 in patients with pulmonary sarcoidosis--a potential marker of disease activity?. Respir Med. 2005; 99(4):396-402. DOI: 10.1016/j.rmed.2004.09.016. View

Imabayashi H, Mori T, Gojo S, Kiyono T, Sugiyama T, Irie R . Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profiling by large-scale cDNA analysis. Exp Cell Res. 2003; 288(1):35-50. DOI: 10.1016/s0014-4827(03)00130-7. View

Junker N, Johansen J, Hansen L, Lund E, Kristjansen P . Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005; 96(3):183-90. PMC: 11158589. DOI: 10.1111/j.1349-7006.2005.00026.x. View

Koutroubakis I, Petinaki E, Dimoulios P, Vardas E, Roussomoustakaki M, Maniatis A . Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003; 18(3):254-9. DOI: 10.1007/s00384-002-0446-z. View

Stokes D, Liu G, Coimbra I, Piera-Velazquez S, Crowl R, Jimenez S . Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum. 2002; 46(2):404-19. DOI: 10.1002/art.10106. View

10.

Ober C, Chupp G . The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol. 2009; 9(5):401-8. PMC: 3018778. DOI: 10.1097/ACI.0b013e3283306533. View

11.

Rehli M, Krause S, Andreesen R . Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997; 43(2):221-5. DOI: 10.1006/geno.1997.4778. View

12.

Ostergaard C, Johansen J, Benfield T, Price P, Lundgren J . YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol. 2002; 9(3):598-604. PMC: 119997. DOI: 10.1128/cdli.9.3.598-604.2002. View

13.

Dupont J, Tanwar M, Thaler H, Fleisher M, Kauff N, Hensley M . Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004; 22(16):3330-9. DOI: 10.1200/JCO.2004.09.112. View

14.

Morrow D, de Lemos J . Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115(8):949-52. DOI: 10.1161/CIRCULATIONAHA.106.683110. View

15.

Steenbakkers P, Baeten D, Rovers E, Veys E, Rijnders A, Meijerink J . Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies. J Immunol. 2003; 170(11):5719-27. DOI: 10.4049/jimmunol.170.11.5719. View

16.

Johansen J . Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006; 53(2):172-209. View

17.

Nishikawa K, Millis A . gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003; 287(1):79-87. DOI: 10.1016/s0014-4827(03)00069-7. View

18.

Vos K, Miltenburg A, van Meijgaarden K, van den Heuvel M, Elferink D, van Galen P . Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology (Oxford). 2001; 39(12):1326-31. DOI: 10.1093/rheumatology/39.12.1326. View

19.

Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K . Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008; 7:41. PMC: 2415112. DOI: 10.1186/1476-4598-7-41. View

20.

Joosten L, Helsen M, Lubberts E, Boots A, van den Berg W, Miltenburg A . Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis. Arthritis Rheum. 2000; 43(3):645-55. DOI: 10.1002/1529-0131(200003)43:3<645::AID-ANR22>3.0.CO;2-O. View